Bako Diagnostics is committed to providing updates regarding this ongoing litigation as necessary to ensure that complete and accurate information is available to the podiatric medical community. We do not use eBlasts to communicate this information.
ATLANTA. Jan. 4 -- In 2018, Bako Diagnostics continued a long tradition of supporting the podiatric medical community. These efforts and commitments will continue [...]
ATLANTA. Nov. 19 – Robert C. Alberhasky, MD, a long-time pathologist at Bako Diagnostics and a leader in the podiatric community, died on Saturday, [...]
ATLANTA/BOSTON—October 10, 2018— Bako Diagnostics and StrataDx announce a strategic relationship. The parent company of Bako Diagnostics has acquired StrataDx, a leading U.S. dermatopathology [...]
ATLANTA — July 24, 2018 — Bako Diagnostics, a podiatry-focused clinical laboratory and products company, announced today the appointment of Ted Hull as Chief [...]
ATLANTA — July 11, 2018 — Bako Diagnostics (BakoDx), the leader in nail dystrophy diagnostic testing, announced the availability of its expanded molecular test [...]
ATLANTA. Feb. 26, 2018 – Bako Diagnostics, a podiatry-focused clinical laboratory and products company, announced today that they have formed a Podiatric Advisory Board [...]
ATLANTA. Feb. 26, 2018 – Bako Diagnostics, a podiatry-focused clinical laboratory and products company, announced appointments to the Bako Clinical Consultant Team. This Team [...]
Company changes name to Bako Diagnostics and redesigns logo to reflect increased clinical laboratory services for podiatrists ATLANTA. Dec. 15 /PRNewswire/ - Bako, [...]
